|
Name |
Verticillin A
|
Molecular Formula | C30H28N6O6S4 | |
IUPAC Name* |
(1S,2S,11R,14S)-2-hydroxy-3-[(1S,2S,3S,11R,14S)-2-hydroxy-14,18-dimethyl-13,17-dioxo-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-trien-3-yl]-14,18-dimethyl-15,16-dithia-10,12,18-triazapentacyclo[12.2.2.01,12.03,11.04,9]octadeca-4,6,8-triene-13,17-dione
|
|
SMILES |
C[C@]12C(=O)N3[C@@H]4[C@]([C@@H]([C@@]3(C(=O)N1C)SS2)O)(C5=CC=CC=C5N4)C67[C@@H]([C@]89C(=O)N([C@](C(=O)N8[C@H]6NC1=CC=CC=C71)(SS9)C)C)O
|
|
InChI |
InChI=1S/C30H28N6O6S4/c1-25-21(39)35-19-27(13-9-5-7-11-15(13)31-19,17(37)29(35,45-43-25)23(41)33(25)3)28-14-10-6-8-12-16(14)32-20(28)36-22(40)26(2)34(4)24(42)30(36,18(28)38)46-44-26/h5-12,17-20,31-32,37-38H,1-4H3/t17-,18-,19+,20+,25-,26-,27+,28?,29-,30-/m0/s1
|
|
InChIKey |
IMGTYEJTVRXGLW-LTEJGUQOSA-N
|
|
Synonyms |
Verticillin A; 32164-16-2
|
|
CAS | NA | |
PubChem CID | 101647516 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 696.8 | ALogp: | 1.0 |
HBD: | 4 | HBA: | 12 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 247.0 | Aromatic Rings: | 12 |
Heavy Atoms: | 46 | QED Weighted: | 0.323 |
Caco-2 Permeability: | -5.702 | MDCK Permeability: | 0.00001280 |
Pgp-inhibitor: | 0.953 | Pgp-substrate: | 0.571 |
Human Intestinal Absorption (HIA): | 0.614 | 20% Bioavailability (F20%): | 0.975 |
30% Bioavailability (F30%): | 0.995 |
Blood-Brain-Barrier Penetration (BBB): | 0.159 | Plasma Protein Binding (PPB): | 77.82% |
Volume Distribution (VD): | 1.396 | Fu: | 13.48% |
CYP1A2-inhibitor: | 0.016 | CYP1A2-substrate: | 0.106 |
CYP2C19-inhibitor: | 0.957 | CYP2C19-substrate: | 0.944 |
CYP2C9-inhibitor: | 0.977 | CYP2C9-substrate: | 0.119 |
CYP2D6-inhibitor: | 0.349 | CYP2D6-substrate: | 0.068 |
CYP3A4-inhibitor: | 0.946 | CYP3A4-substrate: | 0.988 |
Clearance (CL): | 7.521 | Half-life (T1/2): | 0.015 |
hERG Blockers: | 0 | Human Hepatotoxicity (H-HT): | 0.132 |
Drug-inuced Liver Injury (DILI): | 0.988 | AMES Toxicity: | 0.007 |
Rat Oral Acute Toxicity: | 0.936 | Maximum Recommended Daily Dose: | 0.842 |
Skin Sensitization: | 0.912 | Carcinogencity: | 0.604 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.006 |
Respiratory Toxicity: | 0.316 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003588 | 0.926 | D0SP3D | 0.237 | ||||
ENC003382 | 0.891 | D01TSI | 0.236 | ||||
ENC003381 | 0.878 | D0E0RY | 0.234 | ||||
ENC004849 | 0.784 | D0W7RJ | 0.233 | ||||
ENC003490 | 0.773 | D0V3ZA | 0.230 | ||||
ENC001500 | 0.658 | D09NNH | 0.225 | ||||
ENC004848 | 0.586 | D0V9WF | 0.219 | ||||
ENC002358 | 0.445 | D0J5YC | 0.215 | ||||
ENC003992 | 0.442 | D0R5OS | 0.208 | ||||
ENC003530 | 0.428 | D02TJS | 0.206 |